Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagent Neoadjuvant Chemotherapy in the Modern Era.
Publication/Presentation Date
9-1-2021
Abstract
BACKGROUND: Neoadjuvant chemotherapy (CT) is being utilized more frequently in patients diagnosed with localized pancreatic cancer. The role of additional neoadjuvant radiotherapy (RT) remains undefined. We explored outcomes associated with neoadjuvant RT in the modern era.
METHODS: The National Cancer Database (2010-2017) was queried for patients with clinical stage II-III pancreatic adenocarcinoma who received neoadjuvant multiagent systemic CT +/- RT. Demographics, pathologic outcomes, postoperative outcomes, and overall survival were compared.
RESULTS: A total of 5245 patients were included, of whom 3123 received CT and 1941 received CT + RT. Use of RT decreased over the 8-year study period. On multivariable analysis, treatment at academic facilities (odds ratio (OR) = 1.52,
DISCUSSION: In patients with stage II-III pancreatic adenocarcinoma, the addition of neoadjuvant RT to multiagent neoadjuvant CT may be associated with increased rates of node-negative and margin-negative resection, as well as improved overall survival.
Volume
87
Issue
9
First Page
1386
Last Page
1395
ISSN
1555-9823
Published In/Presented At
Hue, J. J., Dorth, J., Sugumar, K., Hardacre, J. M., Ammori, J. B., Rothermel, L. D., Saltzman, J., Mohamed, A., Selfridge, J. E., Bajor, D., Winter, J. M., & Ocuin, L. M. (2021). Neoadjuvant Radiotherapy is Associated With Improved Pathologic Outcomes and Survival in Resected Stage II-III Pancreatic Adenocarcinoma Treated With Multiagent Neoadjuvant Chemotherapy in the Modern Era. The American surgeon, 87(9), 1386–1395. https://doi.org/10.1177/00031348211038581
Disciplines
Medicine and Health Sciences
PubMedID
34382877
Department(s)
Department of Surgery, Lehigh Valley Topper Cancer Institute
Document Type
Article
